您現在的位置 :

醫療團隊

專業的醫護人員，提供最佳的醫療服務

醫師介紹

  •

張德生醫師

肝癌超音波介入性治療及藥物治療、B、C型肝炎、消化道內視鏡診療
  • 國語,英語,閩南語
  • 教授
醫師網路掛號
直接點選進入醫師網路掛號畫面
醫師資歷
  • 現職
    • 雲林長庚醫院 胃腸肝膽科 主任
    • 嘉義長庚醫院 胃腸肝膽科 主任
    • 長庚大學中醫系 專任助理教授
    • 嘉義長庚醫院胃腸肝膽科 教授級主治醫師
  • 學歷
    • 高雄醫學院 醫學系 學士
    • 長庚大學 臨床醫學研究所 博士
  • 經歷
    • 嘉義長庚醫院胃腸肝膽科主治醫師
    • 林口長庚醫院內科部住院醫師
    • 林口長庚醫院胃腸肝膽科系住院醫師
  • 學會與認證
    • 台灣內科醫學會專科醫師及指導醫師
    • 台灣消化系醫學會專科醫師及指導醫師
    • 台灣消化系內視鏡醫學會專科醫師
    • 中華民國醫用超音波學會專科醫師
    • 台灣醫學教育學會一般醫學師資
    • 美國癌症研究學會(American Association for Cancer Research) 會員
  • 論文及期刊發表
    • Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.
      Hepatology International 2023;17:550-561.
      Chang TS, Hung CH, et al.
    • Above-standard survival of hepatocellular carcinoma as the final outcome of comprehensive hepatology care programs in a remote HCV-endemic area.
      Viruses 2023;15:786.
      Cho WR, Huang HL, Hsu NT, Huang TJ, Chang TS*.
    • Niclosamide enhances sorafenib sensitivity through IGF-1R and metabolic changes in hepatocellular carcinoma.
      Cancers 2023, 15(3), 931
      Peng SW, Thi Ngo MH, Kuo YC, Teng MH, Chang TS*, Huang YH*.
    • Factors associated with large renal function decline in patients with chronic hepatitis C successfully treated with direct-acting antiviral therapy.
      Diagnostics 2023;13(3),473.
      Chen CH, Shen CH, Wei KL, Xu HW, Chen WM, Chang KC, Huang YT, Hsieh YY, Lu SN, Hung CH, Chang TS*.
    • Direct-acting antivirals reduce the de novo development of esophageal varices in patients with hepatitis C related liver cirrhosis.
      Viruses 2023;15(1):252.
      Hsieh YY, Chen WM, Chang KC, Chang TS*, Hung CH, Yang YH, Tung SY, Wei KL, Shen CH, Wu CS, Ding YJ, Hu JH, Hung YT, Lin MH, Lu CK, Lin YH, Lin MS.
    • Changes in in renal function in chronic hepatitis C patients treated with sofosbuvir/velpatasvir.
      Advances in Digestive Medicine 2022 Apr
      Su PK, Chang TS, Tung SY, Wei KL, Shen CH, Hsieh YY, Chen WM, Chen YH, Chern CH, Yen CW, Xu HW, Tung WL, Chang KC*.
    • Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
      PLoS ONE 2022;17(8):e0272567.
      Lu YH, Lu CK, Chen CH, Tung SY, Chen YH, Yen CW, Tung WL, Chang KC, Chen WM, Lu SN, Hung CH, Chang TS*.
    • Non-B, non-C hepatocellular carcinoma in an HBV- and HCV-endemic area: A community-based prospective longitudinal study.
      Viruses 2022;14(5):984.
      Chang TS, Hsu NT, Chen SC, Hsu IL, Lee MH*, Lu SN*.
    • Targeting galectin-1 inhibits hepatoma progression by inducing ADAM17-mediated TNFR1 shedding in carcinoma-associated fibroblasts.
      Oncogene 2022;41:3011-3023
      Tsai YT, Li CY, Huang YH, Chang TS, Lin CY, Chuang CH, Wang CY, Anuraga G, Shih TC, Chang TH, Lin ZY, Chen YL, Hung II, Lee KH, Chang CC, Yang KH, Tsui WL, Chee-Voon Y, Wu MH*.
    • The novel finding of dynamic change of eGFR to one year after end-of-treatment in HCV-infected patients receiving sofosbuvir and velpatasvir.
      Viruses 2022;14:362
      Wu CK, Chen LW, Chang TS, Tung SY, Lin CY, Hung CH, Lu SN, Chien RN, Lin CL, Chen CH, Hsu CW, Hu TH*, Sheen IS*
    • Factors associated with significant platelet count improvement in thrombocytopenic chronic hepatitis C patients receiving direct-acting antivirals.
      Viruses 2022;14:333.
      Chen YC*, Chang TS*, Chen CH, Cheng PN, Lo CC, Mo LR, Chen CT, Huang CF, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Dai CY, Kao JH, Chuang WL, Lin HC, Chen CY, Tseng KC*, Yu ML*
    • Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
      J Formos Med Assoc 2022;121)8)1567-1578
      Lo CC, Huang CF, Cheng PN, Tseng KC, Chen CY, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, et al.
    • Community-based screening for hepatitis B and C virus activity using two quantitative antigens to identify endemic townships.
      Viruses 2022;14:304
      Huang WC, Lin YC, Chen PJ, Hsu NT, Tu CL, Chang TS, Hung CH, Kee KM, Chao WH, Lu SN.
    • Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
      Sci Rep 2021;11:23473.
      Huang CF, Kuo HT, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, J Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC*, Yu ML*
    • Fusobacterium nucleatum infection is associated with decreased survival of Helicobacter pylori-positive gastric cancer patients.
      World J Gastroenterol 2021;27:7311-7323.
      Hsieh YY, Tung SY, Pang HY, Chang TS, Wei KL, Chang WM, Deng YF, Lu CK, Lai YH, Wu CS, Li C*
    • A Yes-associated protein (YAP) and insulin-like growth factor 1 receptor (IGF-1R) signaling loop is involved in sorafenib resistance in hepatocellular carcinoma.
      Cancers 2021,13(15), 3812
      Thi Ngo MH, Peng SY, Kuo YC, Lin CY, Wu MH, Chuang CH, Kao CX, Jeng HY, Lin GY, Ling TY, Chang TS*, Huang YH*
    • Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV reflex HCV antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study.
      BMJ Open 2021;11:e046115.
      Chang TS, Chang KC, Chen WM, Hsu NT, Lee CY, Lin YC, Huang WC, Chiu WN, Hu JH, Huang TJ, Chen MY, Lu SN.
    • Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.
      Sci Rep 2021:11:13543.
      Chang KC, Tung SY, Wei KL, Shen CH, Hsieh YY, Chen WM, Chen YH, Chen CH, Yen CW, Xu HW, Tung WL, Chang TS*
    • Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: a real-world effectiveness analysis.
      J Gastroenterol Hepatol 2021;36:2911-2916.
      Ding YJ, Lu CK, Chen WM, Tung SY, Chang KC, Wei KL, Shen CH, Hsieh YY, Yen CW, Hung CH, Lu SN, Chang TS*
    • Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan.
      BMC Gastroenterol 2021;21:259
      Huang YT, Hsieh YY, Chen WM, Tung SY, Wei KL, Shen CH, Chang KC, Lu CK, Yen CW, Lu SN,, Hung CH, Chang TS*
    • The role of IGF/IGF-1R signaling in hepatocellular carcinomas: Stemness-related properties and drug resistance.
      Int J Mol Sci 2021;22:1931
      Thi Ngo MH, Jeng HY, Kuo YC, Nanda JD, Brahmadhi A, Ling TY*, Chang TS*, Huang YH*
    • Immuno-metabolism: The role of cancer niche in immune checkpoint inhibitor resistance.
      Int J Mol Sci 2021;22:258
      Weng CY, Kao CX, Chang TS*, Huang YH*
    • Epigenetic silencing of STAT3-targeted miR-193a, by constitutive activation of JAK/STAT signaling, leads to tumor progression through overexpression of YWHAZ in gastric cancer.
      Front Oncol (SCI) 2021;11:575667.
      Wei KL, Chou JL, Chen YC, Lin GL, Liu JL, Chang TS, Chen WM, Hsieh YY, Yan PS, Chuang YM, Lin JM, Wu SF, Chiang MK, Li C, Wu CS, Chan MWY.
    • Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B.
      Sci Rep 2021;11:1365.
      Chang TS*, Yang YH*, Chen WM, Tung SY, Shen CH, Yen CW, Hsieh YY, Lee CB, Ling TM, Hung CH, Lu SN.
    • Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening.
      J Formos Med Assoc 2021;120:847–853.
      Chang KC, Lee CY, Chang TS, Hung CH, Chen WM, Chen MY, Hung TJ, Chiu WN, Hu JH, Lin YC, Huang WC, Hsu NT, Lu SN.
    • Challenges of transferring rural adults with chronic HCV infection for further HCVRNA confirmation and free DAAs treatment: a success story of interdisciplinary collaboration approach.
      BMC Infect Dis (SCI) 2020;20:737.
      Li W*, Chang TS*, Chang SZ, Chen CH, Chen MY.
    • High viral load predicts virological failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
      J Formos Med Assoc 2020;11:1593–1600.
      Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, Hsieh YY, Chiu WN, Hu JH, Lu SN, Hung CH.
    • 2,4-diamino-quinazoline, a Wnt signaling inhibitor, suppresses gastric cancer progression and metastasis.
      nt J Mol Sci 2020:21;5901
      Chang TS, Lu CK, Hsieh YY, Wei KL, Chen WM, Tung SY, Wu CS, Chiang MK.
    • Real world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: a multicenter pooled analysis in Taiwan.
      J Viral Hepat 2020;27:866–872.
      Chiu WN, Hung CH, Lu SN, Chen MY, Tung SY, Wei KL, Lu CK, Chen CH, Hu TH, Hu JH, Chen WM, Chang TS*
    • Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
      PLoS ONE (SCI) 2020;15(3): e0229994.
      Lin SF, Tung SY, Wei KL, Chen CH, Hu TH, Shen CH, Chang TS, Chen WM, Yen CW, Wang JH, Lu SN, Hung CH.
    • Liver health literacy and health status among adults with hepatitis C: implications for the nursing profession as part of the 2030 global elimination goal.
      J Nurs Scholarsh (SCI) 2020:52;128–135.
      Lin YC, Chiu WN, Chang TS, Huang TJ, Chen MY.
    • Limited effects of antibiotic prophylaxis in patients with Child–Pugh class A/B cirrhosis and upper gastrointestinal bleeding.
      PLoS ONE (SCI) 2020;15(2): e0229101.
      Chang TS, Tsai YH, Lin YH, Chen CH, Lu CK, Huang WS, Yang YH, Chen WM, Hsieh YY, Wu YC, Tung SY, Huang YH.
    • Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin.
      J Formos Med Assoc 2020;119:532–537.
      Chen CC, Tung SY, Wei KL, Shen CH, Chang TS, Chen WM, Xu HW, Yen CW, Chen YH, Lu SN, Hung CH.
    • DNMT3b/OCT4 expression confers poor prognosis and sorafenib sensitivity of hepatocellular carcinoma trough IL-6/STAT-3 regulation.
      J Exp Clin Cancer Res 2019;38:474
      Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS*, YH Huang*
    • Esophageal perforation caused by a central venous catheter: a case report and literature review.
      Adv Dig Med 2019;1-4
      Chen WM, Chiang MS, Wang PC, Wei KL, Tung SY, Chang TS, Hung CH.
    • An investigation of the side effects, patient feedback, and physiological changes associated with direct-acting antiviral therapy for hepatitis C.
      Int J Environ Res Public Health 2019;16:4981
      Wu PS*, Chang TS*, Lu SN, Su HJ, Chang SZ, Hsu CW, Chen MY.
    • Prevalence and predictive value of high rheumatoid factor and anti-citrullinated protein antibody levels in nonarthritic patients with chronic hepatitis C infection.
      Int J Rheum dis 2019;22:116–120.
      Lin KM, Chen WM, Tung SY, Wei KL, Shen CH, Chang TS, Chang PJ.
    • Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation.
      Sci Rep 2018;8:16611
      Chu MO, Shen CH, Chang TS, Xu HW, Yen CW, Lu SN, Hung CH
    • The clinical roles of rheumatic factor in the treatment of chronic hepatitis C infection.
      Int J Clin Exp Med 2017;10:9456-9462.
      Chen WM, Chang KC, Lin KM, Wei KL, Chang PJ, Chang TS, Shen CH, Tung SY.
    • Inhibition of CCAR1, a coactivator of β-catenin, suppresses the proliferation and migration of gastric cancer cells
      Int J Mol Sci 2017;18:460; doi:10.3390/ijms18020460
      Chang TS, Wei KL, Chen YH, Cheng YT, Tung SY, Wu CS, Chiang MK.
    • Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
      World J Surg Oncol 2016;14:140.
      Chen WM, Wei KL, Chen YS, Chang PJ, Tung SY, Chang TS, Huang HC, Shen CH, Hsieh YY, Wu CS.
    • Inflammation promotes expression of stemness-related properties in HBV-related hepatocellular carcinoma.
      PLoS ONE. 2016; 11(2):e0149897. doi:10.1371/journal.pone.0149897
      Chang TS, Chen CL, Wu YC, Liu JJ, Kuo YC, Lee KF, Lin SY, Lin SE, Tung SY, Kuo LM, Tsai YH, Huang YH.
    • Hepatoprotective effect of esveratrol against ethanol-induced oxidative stress through induction of superoxide dimutase in vivo and in vitro.
      Exp Ther Med. 2016;11:1231-1238.
      Chen WM, Shaw LH, Chang PJ, Tung SY, Chang TS, Shen CH, Wei KL.
    • Distribution of fatal Vibrio vulnificus necrotizing skin and soft-tissue infections: a systematic review and meta-analysis.
      Medicine 2016; 95(5) pe2627 doi: 10.1097/MD.0000000000002627
      Huang KC, Weng HH, Yang TY, Chang TS, Huang TW, Lee MS.
    • TGF-βI regulates cell migration through pluripotent transcription factor OCT4 in endometriosis.
      PLoS ONE 2015:10(12):e0145256. doi:10.1371/journal.pone.0145256
      Au HK, Chang JH, Wu YC, Kuo YC, Chen YH, Lee WC, Chang TS, Lan PC, Kuo HC, Lee KL, Lee MT, Tzeng CR, YH Huang.
    • Response to Braillon Hepatocellular carcinoma surveillance: A strategy that merits moving forward.
      Am J Gastroenterol 2015;110:1625–1627.
      Chang TS, Wu YC, Tsai YH, Huang YH.
    • Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis.
      Am J Gastroenterol 2015;110:836–844.
      Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS, Tsai YH, Huang YH.
    • Bupivacaine induces apoptosis through caspase-dependent and -independent pathways in canine mammary tumor cells.
      Res Vet Sci 2015;100:232-238.
      Chiu YS, Cheng YS, Lin SW, Chang TS, Liou CJ, Lai YS.
    • Activation of IL6/IGF-IR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression.
      Clin Cancer Res 2015;21:201-210.
      Chang TS, Wu YC, Chi CC, Su WC, Chang PJ, Lee KF, Tung TH, Wang J, Liu JJ, Tung SY, Kuo LM, Ho HN, Ling TY, Huang YH.
    • Outcomes of endoscopic submucosal dissection for early gastric cancer and precancer lesion: Experience from a center in Southern Taiwan.
      Advances in Digestive Medicine 2015:2:95-101.
      Hsieh YY, Lee IL, Wei KL, Chang TS, Tung SY, Wu CS, Lin YH.
    • Resistin-induced stromal cell-derived factor-1 expression through Toll-like receptor 4 and activation of p38 MAPK/ NFκB signaling pathway in gastric cancer cells.
      J Biomed Sci 2014;21:59.
      Hsieh YY, Shen CH, Huang WS, Chin CC, Kuo YH, Hsieh MC, Yu HR, Chang TS, Lin TH, Chiu YW, Chen CN, Kuo HC, Tung SY.
    • Routine blood tests to predict liver fibrosis in chronic hepatitis C.
      World J Gastroenterol 2012; 18:727-846.
      Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, Lin YH.
    • Serum HCV RNA level is not associated with the presence of insulin resistance and metabolic syndrome in chronic hepatitis C patients with genotype 1 or 2 infection.
      Chang Gung Medical Journal 2011;34:487-495.
      Huang HC, Chuang CS, Hsieh YY, Chang TS, Wei KL, Shen CH, Wu CS, Tung SY.
    • Antibiotic strategy for pyogenic liver abscess: one medical center experience in Taiwan.
      Advances in Digestive Medicine 2010;27:1-11.
      Chang TS, Tung SY, Tai DI, Lee IL, Shen CH, Wei KL, Chuang CS, Hsieh YY, Wu CS.
    • Paraesophageal hernia complicated with mediastinal abscess: Report of a case.
      Gastroenterological J Taiwan (2009) 26:202-206.
      Chuang CS, Tung SY, Lee IL, Shen CH, Wei KL, Chang TS, Wu CS.
    • FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis.
      Chang Gung Med J (2009) 32:614-622.
      Hsieh YY, Tung SY, Lee IL, Lee KF, Shen CH, Wei KL, Chang TS, Chuang CS, Wu CS, Lin YH.
    • Clinical features and outcome of chronic viral hepatitis with acute exacerbation in patients with concurrent infections of hepatitis B and C virus.
      Dig Dis Sci (2008) 53:511-516.(SCI)
      Chuang CS, Tung SY, Lee IL, Shen CH, Wei KL, Chang TS, Wu CS.
    • Endoscopic submucosal dissection for early gastric cancers: experience from a new endoscopic center in Taiwan.
      J Clin Gastroenterol (2008) 42:42-47.(SCI)
      Lee IL. Wu CS, Tung SY, Lin PY, Shen CH, Wei KL, Chang TS.
    • Stapled hemorrhoidopexy for prolapsed hemorrhoids in patients with liver cirrhosis; a preliminary outcome for 8-case experience.
      Int J colorectal Dis (2007) 22:1083-1089.(SCI)
      Huang WS, Lin PY, Chin CC, Yeh CH, Hsieh CC, Chang TS, Wang JY.
    • Effect of oral esomeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.
      J Gastroenterol Hepatol. (2007) 22:43-46.(SCI)
      Wei KL, Tung SY, Sheen CH, Chang TS, Lee IL. Wu CS.
    • Successful treatment of pancreatic ascites by endoscopic pancreatic duct stenting: Report of a case.
      Gastroenterological J Taiwan (2007) 24:199-203.
      Chang TS, Wei KL, Lee IL, Sheen CH, Tung SY, Wu CS, Chuang CS.
    • Strangulated obturator hernia- a rare cause of small bowel obstruction: Report of a case.
      Gastroenterological J Taiwan (2005) 22:335-340.
      Wei KL, Sheen CH, Chang TS, Lee IL, Tung SY, Wu CS, Tseng YP.
    • Hepatitis C virus infection facilitates gallstone formation.
      J Gastroenterol Hepatol. (2005) 20:1416-1421.
      Chang TS, Lo SK, Shyr HY, Fang JT, Lee WC,Tai DI, Sheen IS, Lin DY, Chu CM, Liaw YF.
    • Application of lugol chromoendoscopy on the diagnosis of early esophageal cancer.
      J Int Med Taiwan (2005) 16:162-168.
      Chang TS, Lin CJ, Huang WS.
    • Gingival metastasis from gallbladder cancer, a case report.
      Chang Gung Med J. (2002) 25:553-556.
      Chang TS, Liaw CC, Lee KF, Wu CS.